A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 310 participants.

Also called NCT01652703

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 310 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01652703
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01652703. Randomized; triple masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2013-05-14 (actual). Results posted on 2015-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
Acronym
AMG145
Condition
Hypercholesterolemia and High Risk for Cardiovascular Events
Intervention (Biological)
Evolocumab
Intervention (Other)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01652703
Content hash
9f663e5e8336cbe2adbac647aef9aff3b922e97cee224d77c6e2c82384978c5b